In the present study, we found that most of the RTK receptors and ligands were activated during the treatment of thyroid cancer cells with the BRAF inhibitor vemurafenib, while SHP2, a key protein downstream of the RTK signaling pathway, was also activated. This evidence concerns the gene BRAF and thyroid cancer.